Composition

Each capsule of Flurazine 5 contains :

• Flunarizine HCl: 5.9 mg (equivalent to 5 mg flunarizine base).
• Excipients: S.Q. for one Capsule.

Indications

Flurazine is indicated in:

• Prophylaxis of classic (with aura) or common (without aura) migraine.
• Symptomatic treatment of vestibular vertigo (due to a diagnosed functional disorder of the vestibular system).

Dosage & Administration

Migraine Prophylaxis:

Starting Dose: Two 5 mg capsules  of Flurazine at night in patients less than 65 years of age and 5 mg daily in patients older than 65 years.

If, during this treatment depressive, extrapyramidal or other unacceptable symptoms occur, administration should be discontinued.

If, after 2 months of this initial treatment, no significant improvement is observed, the patient should be considered a non-responder and administration should be discontinued.

Maintenance Treatment:

If a patient is responding satisfactorily and if a maintenance treatment is needed, the dose should be decreased to 5 days treatment at the same daily dose with two successive medicine-free days every week.

Even if the prophylactic maintenance treatment is successful and well tolerated, it should be interrupted after 6 months and it should be re-initiated only if the patient relapses.

Vertigo:

The same dosage should be used as for migraine, but the starting treatment should not be given longer than needed for symptom control, which generally takes less than two months.

If after one month of treatment for chronic vertigo or after two months treatment for paroxysmal vertigo, no significant improvement is observed, the patient should be considered a non-responder and administration should be discontinued.